Blocking an endocannabinoid-degrading enzyme protected worm dopamine neurons from Parkinson's-like damage | Research

The takeaway

Inhibiting the enzyme FAAH-4 in C. elegans worms protected dopaminergic neurons from 6-OHDA toxicity, improved survival, and enhanced food-seeking behavior through an antioxidant mechanism mediated by 2-AG.

Neuroscientists studying the endocannabinoid system in neurodegeneration, Parkinson's disease researchers, and evolutionary biologists studying conserved neuroprotective pathways.

FAAH-4 inhibition protected dopamine neurons while direct anandamide did not

What the researchers found

The FAAH-4 inhibitor JZL184 protected dopaminergic neurons from 6-OHDA damage, increased worm survival, and improved food-seeking behavior. A FAAH-4 knockout strain confirmed this protection. The mechanism involved 2-AG-mediated antioxidant responses through gst-4 gene upregulation.

Why it matters

The endocannabinoid system is conserved from worms to humans. Finding that endocannabinoid-boosting strategies protect dopamine neurons in a simple organism suggests this pathway has ancient neuroprotective functions worth exploring for Parkinson's.

The numbers in context

Anandamide (1-100 uM): no protection. JZL184 (50 uM): protected dopaminergic neurons, increased survival, improved food seeking. FAAH-4 knockout worms were more resistant to 6-OHDA. Both JZL184 and 2-AG (1-100 uM) reduced ROS at 24 hours.

How the study worked

C. elegans nematode study testing anandamide (1-100 uM) and the FAAH-4 inhibitor JZL184 against 6-OHDA-induced neuronal damage, with genetic confirmation using a faah-4 knockout strain and antioxidant reporter strain.

What this study cannot tell us

C. elegans is an extremely simple organism compared to the human brain. The jump from worm neuroprotection to human Parkinson's treatment is enormous. JZL184 affects multiple enzymes, not just FAAH-4.

How to read the evidence

Well-controlled worm study with genetic validation, but the enormous biological distance from C. elegans to human brain limits direct translational conclusions.

When this study was published

Published in 2025.

The bigger picture

Parkinson's treatments primarily manage symptoms. Finding that endocannabinoid system modulation can protect the actual neurons that degenerate opens a potential avenue for disease-modifying therapy, with evidence this protection is evolutionarily conserved.

Questions still open

Does FAAH inhibition protect dopaminergic neurons in mammalian Parkinson's models? Which specific endocannabinoid (2-AG vs AEA) is more important for neuroprotection?

Common questions

Can endocannabinoids protect dopamine neurons?

In this worm study, boosting endocannabinoid levels by blocking their breakdown protected dopamine neurons from a Parkinson's-relevant toxin. This protection was mediated by the endocannabinoid 2-AG through antioxidant mechanisms.

Why use worms to study Parkinson's disease?

C. elegans worms have a simple dopamine system that allows rapid genetic and pharmacological testing. Finding that endocannabinoid-based neuroprotection works in this ancient organism suggests the mechanism is evolutionarily conserved.

Read the original research

The Inhibition of Fatty Acid Amide Hydrolase-4 Affords Neuroprotection in a Toxic Model Induced by 6-Hydroxydopamine in Caenorhabditis elegans Nematodes.

Molecular neurobiology, 62(10), 12984-12999

View on PubMed ↗Publisher’s paper ↗

Citation

Estrada-Valencia, Rubén; Túnez, Isaac; Tinkov, Alexey A; Aschner, Michael; López-Goerne, Tessy; Pedraza-Chaverrí, José; Santamaría, Abel. (2025). The Inhibition of Fatty Acid Amide Hydrolase-4 Affords Neuroprotection in a Toxic Model Induced by 6-Hydroxydopamine in Caenorhabditis elegans Nematodes.. Molecular neurobiology, 62(10), 12984-12999. https://doi.org/10.1007/s12035-025-05104-z